Cargando…

Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer

This study aimed to present a comprehensive assessment of anaplastic lymphoma kinase (ALK) rearrangements evaluated by DNA/RNA‐based next‐generation sequencing (NGS) and Ventana immunohistochemistry (IHC) in patients with non‐small‐cell lung cancer (NSCLC) and to evaluate the therapeutic outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ruiying, Guo, Lianying, Zhang, Bo, Zhao, Jikai, Xiang, Chan, Chen, Shengnan, Shao, Jinchen, Zhu, Lei, Ye, Min, Han, Yuchen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535099/
https://www.ncbi.nlm.nih.gov/pubmed/35848751
http://dx.doi.org/10.1002/cjp2.289
_version_ 1784802692776853504
author Zhao, Ruiying
Guo, Lianying
Zhang, Bo
Zhao, Jikai
Xiang, Chan
Chen, Shengnan
Shao, Jinchen
Zhu, Lei
Ye, Min
Han, Yuchen
author_facet Zhao, Ruiying
Guo, Lianying
Zhang, Bo
Zhao, Jikai
Xiang, Chan
Chen, Shengnan
Shao, Jinchen
Zhu, Lei
Ye, Min
Han, Yuchen
author_sort Zhao, Ruiying
collection PubMed
description This study aimed to present a comprehensive assessment of anaplastic lymphoma kinase (ALK) rearrangements evaluated by DNA/RNA‐based next‐generation sequencing (NGS) and Ventana immunohistochemistry (IHC) in patients with non‐small‐cell lung cancer (NSCLC) and to evaluate the therapeutic outcomes of ALK tyrosine kinase inhibitor (TKI) treatment. We investigated ALK gene fusions in 14,894 patients with NSCLC using Ventana IHC and NGS, including 12,533 cases detected via DNA‐based NGS and 2,361 cases using RNA‐based NGS. The overall percentage agreement (OPA), positive percentage agreement (PPA), and negative percentage agreement (NPA) were calculated when comparing the results between NGS and IHC. The therapeutic responses to ALK‐TKIs were also evaluated. In total, 3.50% (439/12,533) of specimens were NGS ALK‐positive (NGS‐p) in the DNA‐based NGS cohort and 3.63% (455/12,533) were IHC ALK‐positive (IHC‐p). The OPA of NGS was 99.60%, whereas its PPA and NPA were 92.75 and 99.86%, respectively. In the adenocarcinoma (ADC) subcohort, the PPA was 95.69%. In the RNA‐based NGS cohort, 2.20% (52/2,361) of specimens were NGS‐p and 2.63% (62/2,361) were IHC‐p. The OPA of NGS was 99.49%; its PPA and NPA were 82.26 and 99.96%, respectively. Thirteen patients with discordant results received ALK‐TKI treatment. In the seven NGS‐p/IHC‐negative (IHC‐n) patients, the overall response rate (ORR) was 85.4% (6/7) and the disease control rate (DCR) was 100%. In the six NGS‐negative/IHC‐p patients, the ORR was 66.7% (4/6) and the DCR was 100%. In summary, a high concordance of ALK gene fusion detected via NGS and IHC was observed in this study. DNA‐based NGS had a higher OPA, PPA, and PPA in the ADC subcohort, whereas RNA‐based NGS had a higher NPA. Overall, the results suggest that the combination of NGS and IHC can improve the accuracy of ALK fusion detection; hence, a result determination algorithm for clinical detection of ALK gene fusion was also proposed.
format Online
Article
Text
id pubmed-9535099
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-95350992022-10-11 Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer Zhao, Ruiying Guo, Lianying Zhang, Bo Zhao, Jikai Xiang, Chan Chen, Shengnan Shao, Jinchen Zhu, Lei Ye, Min Han, Yuchen J Pathol Clin Res Original Articles This study aimed to present a comprehensive assessment of anaplastic lymphoma kinase (ALK) rearrangements evaluated by DNA/RNA‐based next‐generation sequencing (NGS) and Ventana immunohistochemistry (IHC) in patients with non‐small‐cell lung cancer (NSCLC) and to evaluate the therapeutic outcomes of ALK tyrosine kinase inhibitor (TKI) treatment. We investigated ALK gene fusions in 14,894 patients with NSCLC using Ventana IHC and NGS, including 12,533 cases detected via DNA‐based NGS and 2,361 cases using RNA‐based NGS. The overall percentage agreement (OPA), positive percentage agreement (PPA), and negative percentage agreement (NPA) were calculated when comparing the results between NGS and IHC. The therapeutic responses to ALK‐TKIs were also evaluated. In total, 3.50% (439/12,533) of specimens were NGS ALK‐positive (NGS‐p) in the DNA‐based NGS cohort and 3.63% (455/12,533) were IHC ALK‐positive (IHC‐p). The OPA of NGS was 99.60%, whereas its PPA and NPA were 92.75 and 99.86%, respectively. In the adenocarcinoma (ADC) subcohort, the PPA was 95.69%. In the RNA‐based NGS cohort, 2.20% (52/2,361) of specimens were NGS‐p and 2.63% (62/2,361) were IHC‐p. The OPA of NGS was 99.49%; its PPA and NPA were 82.26 and 99.96%, respectively. Thirteen patients with discordant results received ALK‐TKI treatment. In the seven NGS‐p/IHC‐negative (IHC‐n) patients, the overall response rate (ORR) was 85.4% (6/7) and the disease control rate (DCR) was 100%. In the six NGS‐negative/IHC‐p patients, the ORR was 66.7% (4/6) and the DCR was 100%. In summary, a high concordance of ALK gene fusion detected via NGS and IHC was observed in this study. DNA‐based NGS had a higher OPA, PPA, and PPA in the ADC subcohort, whereas RNA‐based NGS had a higher NPA. Overall, the results suggest that the combination of NGS and IHC can improve the accuracy of ALK fusion detection; hence, a result determination algorithm for clinical detection of ALK gene fusion was also proposed. John Wiley & Sons, Inc. 2022-07-18 /pmc/articles/PMC9535099/ /pubmed/35848751 http://dx.doi.org/10.1002/cjp2.289 Text en © 2022 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Zhao, Ruiying
Guo, Lianying
Zhang, Bo
Zhao, Jikai
Xiang, Chan
Chen, Shengnan
Shao, Jinchen
Zhu, Lei
Ye, Min
Han, Yuchen
Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
title Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
title_full Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
title_fullStr Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
title_full_unstemmed Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
title_short Identification and therapeutic evaluation of ALK rearrangements in non‐small‐cell lung cancer
title_sort identification and therapeutic evaluation of alk rearrangements in non‐small‐cell lung cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9535099/
https://www.ncbi.nlm.nih.gov/pubmed/35848751
http://dx.doi.org/10.1002/cjp2.289
work_keys_str_mv AT zhaoruiying identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT guolianying identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT zhangbo identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT zhaojikai identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT xiangchan identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT chenshengnan identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT shaojinchen identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT zhulei identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT yemin identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer
AT hanyuchen identificationandtherapeuticevaluationofalkrearrangementsinnonsmallcelllungcancer